Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of BI 907828 (Brigimadlin) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours

NCT05512377 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT05512377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05512377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of BI 907828 (Brigimadlin) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
December 13, 2022
Completion date
September 25, 2025
Enrollment
99 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer, bladder cancer, lung neoplasms, pancreatic neoplasms, solid tumors